Electronic Common Technical Document (eCTD)

The eCTD is the standard format for submitting applications, amendments, supplements, and reports to FDA’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER).

Important Dates

After the dates listed below, eCTD requirements for submissions to CDER and CBER will go into effect and submissions that do not use eCTD will not be filed or received.

  • May 5, 2017: New Drug Applications (NDAs), Abbreviated NDAs (ANDAs), and Biologics License Applications (BLAs), must be submitted using eCTD format.
  • May 5, 2018: Commercial Investigational New Drug Applications (INDs) and Master Files must be submitted using eCTD format.
  • Please refer to the eCTD Guidance for the complete details to meet the eCTD requirement.

Visit our Submit Using eCTD page to learn how to submit an application using eCTD and obtain an ESG account.
To view all eCTD Submission Resources, visit our eCTD Resources page.

Electronic submission requirements will apply to the following types of submissions to CDER/CBER:

  • NDAs
  • ANDAs
  • BLAs
  • Commercial IND applications (for products that are intended to be distributed commercially)
  • All subsequent submissions to these types of applications, including amendments, supplements, and reports, even if the original submission was filed before the requirements went into effect
  • Master files, such as DMFs, which are considered to be submissions to an IND, an NDA, an ANDA, or a BLA

Electronic submission standards will be optional but encouraged for the following categories:

  • Noncommercial INDs, such as investigator-sponsored INDs and expanded-access INDs
  • Submissions for blood and blood components, including source plasma
  • Submissions for promotional materials for human prescription drug
  • Electronic submissions must use the version of eCTD currently supported by FDA, which is specified in the FDA Data Standards Catalog on the Study Data Standards Resources page. Updates to the standard will be announced on the FDA website and published in the Federal Register. The notices will include the date on which the new versions will go into effect.
  • For a listing of Specifications, Supportive Files, M1 versions 1.3 and 2.3 documents related to eCTD, please refer to eCTD Submission Standards (XLS - 57KB) or eCTD Submission Standards (PDF - 91KB).

Notice 4/7/2017
FDA Extends Compliance Date for Submitting DMFs in eCTD format

The FDA extended the compliance date for submitting DMF’s in eCTD format to May 5, 2018. See the FDA guidance document for additional information on the compliance date and FDA’s Drug Master File page for additional information on DMFs.

Important Notice 5/18/2016
Third Acknowledgement for Successful eCTD Submissions

Beginning May 31, 2016, CDER will begin issuing an acknowledgement to FDA Electronic Submissions Gateway (ESG) users when their NDA, ANDA, BLA, IND, or DMF submission has successfully completed validation and processing and is available to the assigned review division. This acknowledgement is in addition to the ESG Message Delivery Notification acknowledgement (first acknowledgement) and the Official Center acknowledgement (second acknowledgement) and is referred to as the “third acknowledgement.”

For additional notices, please see eCTD Important Notices.

Stay Connected

If you have questions for CDER, please contact the CDER Electronic Submission (ESUB) Support Team at esub@fda.hhs.gov.

If you have questions for CBER, please contact the CBER ESUB Support Team at esubprep@fda.hhs.gov.


Page Last Updated: 02/07/2018
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English